Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia

Uridine diphospho glucuronosyltransferase 2B17 (UGT2B17) glucuronidates androgens and xenobiotics including certain drugs. The UGT2B17 gene shows a remarkable copy number variation (CNV), which predisposes for solid tumors and influences drug response. Here, we identify a yet undescribed UGT2B17 mRN...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2013-02, Vol.121 (7), p.1175-1183
Hauptverfasser:	Gruber, Michaela, Bellemare, Judith, Hoermann, Gregor, Gleiss, Andreas, Porpaczy, Edit, Bilban, Martin, Le, Trang, Zehetmayer, Sonja, Mannhalter, Christine, Gaiger, Alexander, Shehata, Medhat, Fleiss, Karin, Skrabs, Cathrin, Lévesque, Éric, Vanura, Katrina, Guillemette, Chantal, Jaeger, Ulrich
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents - therapeutic use Base Sequence Biomarkers, Tumor - genetics Case-Control Studies Cell Line, Tumor Disease-Free Survival Female Gene Dosage Gene Knockdown Techniques Glucuronosyltransferase - genetics Glucuronosyltransferase - metabolism Humans Kaplan-Meier Estimate Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - enzymology Leukemia, Lymphocytic, Chronic, B-Cell - genetics Male Middle Aged Minor Histocompatibility Antigens Prognosis Risk Factors RNA, Messenger - genetics RNA, Messenger - metabolism RNA, Neoplasm - genetics RNA, Neoplasm - metabolism RNA, Small Interfering - genetics Transcriptome Up-Regulation - drug effects Vidarabine - analogs & derivatives Vidarabine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!